Kyverna Therapeutics

NSQ:KYTX · US5019761049

BiotechnologySmall

360° View

Value1

Price/Sales10

Price/Earnings34

Price/Book5

Dividend Yield—

Growth88

Revenue Growth—

Profit Growth33

Capital Growth100

TSR 52w81

Safety4

Leverage34

Liquidity19

Refinancing23

Combined26

Sentiment27

Analyst Opinions31

Pro Holdings31

Opinion Changes50

Market Pulse51

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2018

Employees140

Websitekyvernatx.com

ISINUS5019761049

Last UpdateApr 2, 2026

Index & Theme

Chronic DiseasesImmunologyNeurologyHematologyRheumatologyGeneticsStem Cell TherapyBiotechnologyLife ScienceTherapeutics

Description

Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company’s approach is supported by its breadth of experience treating patients with its…

Analysis

Kyverna Therapeutics's 360° View rank of 6 places it among the weakest overall — better than 6% of its true peers.

It's a growth standout (88) and expensive versus peers (1). On safety it is highly leveraged (4), and the market shows muted sentiment (27). Taken together, its Combined rank of 26 reads as below its peer average.

360° rank · history

1007550250

2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Kyverna Therapeutics with its peers

Cartesian Therapeutics

NMQ:RNAC

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Cabaletta Bio

NSQ:CABA

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Legend Biotech

NSQ:LEGN

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Nkarta

NSQ:NKTX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Caribou Biosciences

NSQ:CRBU

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Aurinia Pharmaceuticals

NMQ:AUPH

CountryCanada

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →